Asset Details
Do you wish to reserve the book?
Urinary albumin-to-creatinine ratio in patients with hypertension and risk of major cardiovascular events
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Urinary albumin-to-creatinine ratio in patients with hypertension and risk of major cardiovascular events
Do you wish to request the book?
Urinary albumin-to-creatinine ratio in patients with hypertension and risk of major cardiovascular events
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Urinary albumin-to-creatinine ratio in patients with hypertension and risk of major cardiovascular events
2025
Overview
Introduction/aimsEvaluation of urinary albumin-to-creatinine ratio (uACR) is a key component in the management of hypertension, yet there is a lack of data on the association between uACR and major cardiovascular events (MACEs) in large hypertensive cohorts, and it is also unknown how often uACR is measured among these patients.We aimed to evaluate the usage of uACR in a nationwide population of patients with hypertension. Furthermore, we sought to assess the risk of cardiorenal events according to uACR, among patients with hypertension.MethodsWe used Danish nationwide registries to identify patients who initiated antihypertensive treatment. The patients were grouped at treatment initiation according to uACR: normoalbuminuria, microalbuminuria, macroalbuminuria and no uACR measurement, and followed for 2 years, to evaluate the risk of a MACE, hospitalisation for heart failure (HF), 40% decline in estimated glomerular filtration rate (eGFR) and end-stage kidney disease (ESKD) according to uACR.ResultsWe included 144 644 patients, of whom 116 039 (80%) did not have their uACR evaluated at treatment initiation. Patients with macroalbuminuria comprised the greatest 2 year absolute risk of MACE (5.3%, 95% CI: 4.0% to 6.6%) and had a greater risk of MACE (HR: 2.02, 95% CI: 1.54 to 2.66), HF (HR: 1.99, 95% CI: 1.35 to 2.95), 40% decline in eGFR (HR: 4.81, 95% CI: 3.78 to 6.10) and ESKD (HR: 4.52, 95% CI: 3.00 to 6.82) compared with patients with normoalbuminuria. Increased risk of MACE, HF and 40% decline in eGFR among patients with macroalbuminuria was persistent across subgroups of eGFR 120–30 mL/min/1.73 m².ConclusionsIn this real-world cohort, uACR was not regularly measured among patients initiating antihypertensive treatment. Nonetheless, the 2-year risks of cardiorenal events were considerably higher among patients with albuminuria compared with patients without.
Publisher
British Cardiovascular Society,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Aged
/ Antihypertensive Agents - therapeutic use
/ Cardiac Risk Factors and Prevention
/ Cardiovascular Diseases - epidemiology
/ Diabetes
/ Female
/ Humans
/ Hypertension - complications
/ Hypertension - physiopathology
/ Male
/ Outcome Assessment, Health Care
/ Personal identification numbers
/ Proteins
/ STROKE
